Back
Compare AU
Compare DRUG vs. ASIA
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the Betashares Global Healthcare Currency Hedged ETF (DRUG) and the Betashares Asia Technology Tigers ETF (ASIA). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.
Community Stats
DRUG | ASIA | |
|---|---|---|
Popularity | Low | Medium |
Pearlers invested | 74 | 1,307 |
Median incremental investment | $740.50 | $993.12 |
Median investment frequency | Monthly | Monthly |
Median total investment | $1,755.07 | $2,514.60 |
Average age group | 26 - 35 | 26 - 35 |
Key Summary
DRUG | ASIA | |
|---|---|---|
Strategy | DRUG.AX was created on 2016-08-04 by BetaShares. The fund's investment portfolio concentrates primarily on health care equity. DRUG.AX aims to track the performance of an index (before fees and expenses) that comprises the largest global healthcare companies (ex-Australia), hedged into Australian dollars. | ASIA aims to track the performance of the Solactive Asia Ex-Japan Technology & Internet Tigers index. The index consists of the 50 largest technology and online retail stocks in Asia (excluding Japan). |
Top 3 holdings | BRL - BRAZILIAN REAL (0 %) AUD - AUSTRALIA DOLLAR (0 %) CHF - SWISS FRANC (0 %) | SAMSUNG ELECTRONICS CO LTD (17.28 %) SK HYNIX INC (14.66 %) TAIWAN SEMICONDUCTOR MANUFACTU (10.96 %) |
Top 3 industries | Other (75.91 %) Communication Services (33.53 %) Health Care (23.80 %) | Other (78.96 %) Communication Services (11.73 %) Consumer Discretionary (8.74 %) |
Top 3 countries | United States (69.91 %) Switzerland (10.93 %) United Kingdom of Great Britain and Northern Ireland (7.38 %) | China (31.58 %) Taiwan (31.34 %) Korea (28.03 %) |
Management fee | 0.57 % | 0.67 % |
Key Summary
DRUG | ASIA | |
|---|---|---|
Issuer | BetaShares | BetaShares |
Tracking index | Nasdaq Global ex-Australia Healthcare Hedged AUD Index - AUD | Solactive Asia Ex-Japan Technology & Internet Tigers Index |
Asset class | ETF | ETF |
Management fee | 0.57 % | 0.67 % |
Price | $8.71 | $15.24 |
Size | $176.672 million | $1.045 billion |
10Y return | N/A | N/A |
Annual distribution yield (5Y) | 1.92 % | 1.15 % |
Market | ASX | ASX |
First listed date | 08/08/2016 | 21/09/2018 |
Purchase fee | $6.50 | $6.50 |
Community Stats
DRUG | ASIA | |
|---|---|---|
Popularity | Low | Medium |
Pearlers invested | 74 | 1,307 |
Median incremental investment | $740.50 | $993.12 |
Median investment frequency | Monthly | Monthly |
Median total investment | $1,755.07 | $2,514.60 |
Average age group | 26 - 35 | 26 - 35 |
Pros and Cons
DRUG | ASIA | |
|---|---|---|
Pros |
| |
Cons |
|
DRUG | ASIA |
|---|---|
Higher exposure to US market | Lower exposure to US market |
Lower management fee | Higher management fee |
Higher price growth | Lower price growth |
Higher distribution yield | Lower distribution yield |